Medical disclaimer: The information in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Lab results and reference ranges vary by individual, lab, age, sex, and health history. Always consult a qualified healthcare provider before making any decisions about your health, medications, supplements, or lab testing. LabHealthCharts is a data visualization tool — it organizes and displays your lab data, it does not interpret your results or provide medical guidance.

Roughly 30% of adults over 60 have measurable sarcopenia — age-related muscle loss — and the question of how to slow or reverse it has driven serious pharmaceutical research for two decades. ACE-031 sits near the center of that story. It is a fusion protein designed to block signaling through activin receptor type IIA (ActRIIA), the pathway through which myostatin and related ligands suppress muscle growth in the body. In animal studies and early human trials, the approach produced substantial gains in lean mass. And wherever lean mass shifts, several specific blood markers tend to follow.

This article explains what ACE-031 is, what the available clinical data shows, and which biomarkers are most relevant to watch when following research on this compound or related myostatin-pathway modulators. It does not constitute a protocol or endorsement. If you are here because you track your labs and want to understand the biology, read on.

What ACE-031 Is and How It Works

ACE-031 is a recombinant fusion protein that combines the extracellular domain of ActRIIA with a human immunoglobulin Fc region. In plain terms: it acts as a decoy receptor that captures myostatin and related proteins (including activin A and GDF-11) before they can bind to muscle cells and send the "stop growing" signal. The result, observed across preclinical and early clinical studies, is a shift in the muscle-to-fat ratio toward more lean tissue.

Myostatin itself is a member of the TGF-beta (transforming growth factor beta) superfamily. It is produced primarily in skeletal muscle and functions as a negative regulator of muscle mass. When myostatin signaling is reduced or blocked, muscle fiber size and number tend to increase. This mechanism was first described in knockout mice that grew roughly double the normal muscle mass, and later confirmed in rare human cases of myostatin loss-of-function mutations. The research interest behind ACE-031 built on that foundation. For a foundational overview of the myostatin pathway in human physiology, the review by Rodgers and Bhatt in Developmental Cell provides useful context.

A phase 2 trial in boys with Duchenne muscular dystrophy (DMD) was the most advanced human test of ACE-031 before the sponsor, Acceleron Pharma, paused enrollment due to bleeding and telangiectasia adverse events. That trial did demonstrate that a single dose produced measurable increases in lean body mass and reductions in fat mass within weeks, which is part of why the compound remains of interest to researchers and the broader performance community. The trial data and subsequent reporting are described in the Acceleron clinical disclosure and DMD-focused reviews.

Why the Myostatin Pathway Shows Up in Your Labs

Blocking a growth-regulatory pathway at the systemic level is not a local event. ActRIIA is expressed in multiple tissues beyond muscle, including bone, vascular endothelium, and reproductive tissue. That broad expression explains both the potential utility (bone density, lean mass) and the safety concerns observed in the DMD trial (vascular effects). It also means that when researchers study ACE-031 or related molecules, several blood markers change in predictable directions.

Understanding which markers shift, and why, gives you a framework for reading lab data in context rather than in isolation. A creatinine that ticks upward, a phosphorus reading outside the usual range, or an unexpected shift in hemoglobin are not random when you know what pathway is being modulated.

Key Biomarkers to Monitor in ACE-031 Research Contexts

Creatinine and Estimated GFR (eGFR)

Creatinine is a waste product of creatine phosphate metabolism in muscle. The more muscle mass you carry, the more creatinine your muscles produce and release into the bloodstream each day. Estimated GFR (eGFR), which is calculated from creatinine, sex, age, and race using formulas like CKD-EPI, is the standard clinical estimate of kidney filtration capacity.

When lean mass increases substantially, creatinine production rises. That can make eGFR appear lower — not because kidney function has changed, but because the creatinine numerator has gone up. This is a well-documented confound in athletes and bodybuilders, and it is relevant in any context where muscle mass is deliberately increased. Seeing a slight upward drift in creatinine alongside a confirmed increase in lean mass is biologically expected; attributing it to kidney disease without further workup would be a misread. Cystatin C, which is not influenced by muscle mass, is a useful complementary marker if there is genuine concern about renal function.

Phosphorus

Serum phosphorus (normal range typically 2.5–4.5 mg/dL in adults, though ranges vary by lab) is worth watching in any intervention that affects bone or muscle metabolism significantly. ActRIIA signaling influences bone remodeling, and blocking it can increase bone formation markers. Rapid changes in bone turnover can sometimes alter phosphorus handling transiently. In the ACE-031 DMD trial, bone-related markers including bone alkaline phosphatase were among the secondary endpoints specifically because of this pathway overlap.

In practice, phosphorus sits on a standard comprehensive metabolic panel (CMP). A trend upward or downward across several draws is more informative than a single value, which can fluctuate based on diet, time of day, and carbohydrate intake.

Hemoglobin and Hematocrit (CBC)

ActRIIA ligands, particularly activin A and activin B, suppress red blood cell production by interfering with late-stage erythropoiesis in the bone marrow. Blocking ActRIIA signaling therefore tends to increase erythropoiesis and raise hemoglobin and hematocrit values. This is so consistent across the activin receptor blocker class that luspatercept, a closely related molecule, is now FDA-approved specifically to treat anemia in myelodysplastic syndromes and beta-thalassemia based on this mechanism. A 2020 phase 3 trial published in the New England Journal of Medicine showed hemoglobin increases of 1–2 g/dL in treated patients.

For anyone tracking a CBC while following ACE-031 research or related compounds, a rising hemoglobin or hematocrit is an expected pharmacodynamic signal, not a surprise finding. The concern at high levels is polycythemia, which raises blood viscosity and cardiovascular risk. For context, hematocrit above 54% in men or 48% in women is generally where clinical concern begins, though thresholds vary by provider and individual history.

Bone Markers: Bone Alkaline Phosphatase and P1NP

Bone alkaline phosphatase (bone-ALP) and procollagen type 1 N-terminal propeptide (P1NP) are markers of bone formation activity. They are not part of a standard metabolic panel and require separate ordering, but they are relevant here because the ActRIIA pathway has direct effects on osteoblast activity. In the ACE-031 DMD trial, bone-ALP increased significantly, indicating enhanced bone formation. Longer-term trials in muscle-wasting conditions were exploring whether this translated into measurable changes in bone mineral density (BMD) before the program was paused.

For the broader population thinking about bone health alongside muscle health, this is a meaningful connection. Muscle and bone are metabolically linked; what helps one often helps the other, and tracking bone markers over time alongside lean mass indicators can give a more complete picture of musculoskeletal health than either alone. A 2022 review in Frontiers in Physiology covers the muscle-bone crosstalk relevant to this class of compounds.

IGF-1

IGF-1 (insulin-like growth factor 1) is produced primarily by the liver in response to growth hormone signaling and is the main anabolic driver of skeletal muscle growth in adults. While ACE-031 does not directly target the GH/IGF-1 axis, any intervention that substantially changes lean mass and body composition can indirectly affect IGF-1 levels. More practically, many people exploring the performance-and-recovery peptide literature are also following GH-axis compounds (secretagogues like GHRP-2 or tesamorelin), and IGF-1 is the primary tracking marker for that entire class.

IGF-1 reference ranges are strongly age-dependent. A value of 200 ng/mL is toward the high end of normal for a 50-year-old but unremarkable for a healthy 25-year-old. Always evaluate results against age-matched reference intervals. LabHealthCharts tracks IGF-1 as part of the hormone panel — you can view longitudinal trends at labhealthcharts.com/biomarkers/hormone-panel-tracking/igf1-tracking.

Lipid Panel

Body composition changes typically move lipids. Gaining lean mass while losing fat generally improves triglycerides and HDL cholesterol. The lipid panel (total cholesterol, LDL, HDL, triglycerides) is part of any responsible baseline and follow-up when tracking significant physiology changes. There is no specific lipid signal unique to ACE-031, but a lipid panel run at baseline and at 3–6 month intervals gives a clean picture of whether cardiovascular risk markers are trending in a favorable direction alongside any body composition changes.

What the Clinical Safety Data Actually Shows

The DMD pediatric trial was halted after three participants developed nose bleeds and small dilated blood vessels (telangiectasias), likely reflecting the vascular expression of ActRIIA. This is a real adverse signal, not a theoretical one, and it is why ACE-031 has not advanced to later-stage trials. The published safety analysis in Neuromuscular Disorders describes the events in detail. Researchers continue to investigate whether more selective ligand traps that spare vascular activins might achieve the muscle benefit without the vascular liability.

This context matters when you read lab data. Hemoglobin rising predictably is one signal; nosebleeds or unexplained changes in platelet counts or coagulation markers would be separate signals worth bringing to a clinician promptly. The biology is not simple, and tracking only one marker in isolation misses the picture. A CBC that includes red cell, white cell, and platelet data together, checked against a running history, is more informative than any single number.

ACE-031 in the Broader Myostatin-Pathway Research Landscape

Several molecules targeting the same pathway have entered or completed clinical trials in recent years. Luspatercept (Reblozyl) is approved for anemia. Sotatercept targets a related mechanism in pulmonary arterial hypertension and received FDA approval in 2024. Bimagrumab, a monoclonal antibody that blocks ActRIIA and ActRIIB directly rather than acting as a decoy receptor, showed fat mass reduction alongside lean mass preservation in a phase 2 trial in overweight adults and was covered in a 2021 JAMA Network Open report.

Understanding that ACE-031 sits within a class — not as an isolated molecule — is useful. When you see a claim about "myostatin blockers" in the fitness or biohacker space, the clinical reference points are these compounds. The biomarker logic (creatinine, hemoglobin, bone markers, IGF-1) applies across the class, not only to ACE-031 specifically.

Holistic Picture: Muscle, Bone, Blood, and the Bigger Lab Context

Lean muscle mass does not exist in isolation from the rest of your metabolic health. Muscle tissue is the largest site of glucose disposal in the body — more muscle means better insulin sensitivity, which shows up in fasting glucose and HbA1c over time. It is a primary determinant of resting metabolic rate. And as the data from ActRIIA research makes clear, it is tightly linked to bone density, erythropoiesis, and cardiovascular risk.

A meaningful baseline panel for anyone seriously focused on musculoskeletal health — regardless of whether they are following ACE-031 research or simply resistance training and monitoring their progress — would reasonably include: CBC (hemoglobin, hematocrit, platelets), CMP (creatinine, phosphorus, liver enzymes, electrolytes), fasting glucose and HbA1c, lipid panel (total cholesterol, LDL, HDL, triglycerides), IGF-1 with age-matched reference intervals, and 25-OH vitamin D. Bone markers (P1NP, bone-ALP) can be added when bone health is a specific focus.

That is a lot of numbers on a page. What matters is whether those numbers are trending in a consistent direction over months, not whether they each hit a textbook midpoint on a single draw. A creatinine that was 0.85 mg/dL a year ago and is now 1.05 mg/dL tells a different story depending on whether your lean mass has increased. Context is everything, and context is built from repeated measurements.

Biomarkers relevant to myostatin-pathway research and what to expect

Biomarker	Why it matters here	Expected direction with ActRIIA blockade	Note
Creatinine / eGFR	Creatinine reflects muscle mass; eGFR is calculated from it	Creatinine may rise as lean mass increases; eGFR may appear to fall	Not necessarily a kidney concern if lean mass is the driver
Hemoglobin / Hematocrit (CBC)	ActRIIA signaling suppresses late erythropoiesis; blocking it raises RBC production	Hemoglobin and hematocrit likely increase	Monitor for polycythemia risk at high levels
Phosphorus	Bone remodeling activity can alter phosphorus handling	May shift during bone formation responses	Included on standard CMP; track trends, not single values
Bone-ALP / P1NP	Markers of osteoblast (bone-forming cell) activity	Increased in ACE-031 trial data	Requires separate ordering beyond a standard panel
IGF-1	Primary anabolic signal for skeletal muscle; often co-tracked in performance contexts	Indirect; may rise with body composition changes or co-administered GH axis compounds	Strongly age-dependent reference range
Lipid panel	Body composition changes typically improve lipids	Triglycerides and HDL often improve with fat mass reduction	Baseline + 3–6 month follow-up is standard practice
Fasting glucose / HbA1c	More muscle mass generally improves insulin sensitivity	May improve with lean mass gains and fat loss	HbA1c reflects a 3-month average — a useful trend marker

Tracking These Markers Over Time with LabHealthCharts

The biomarkers covered in this article — creatinine, hemoglobin, phosphorus, IGF-1, lipids, glucose — all appear on standard panels from Quest, LabCorp, and most other major labs. The challenge is not getting them measured; it is making sense of how they move together over months and what the direction of travel actually means.

A creatinine of 1.05 mg/dL at one draw means little by itself. Paired with a creatinine of 0.85 mg/dL from 18 months ago, a hemoglobin that has drifted from 14.1 to 15.3 g/dL, and a fasting glucose that has moved from 98 to 91 mg/dL, it starts to tell a story about what is happening to your body composition and metabolic health over time. That is the kind of longitudinal picture a single lab PDF cannot show you.

LabHealthCharts is built for exactly this: upload lab PDFs from any major lab, and AI-assisted extraction pulls 100+ biomarkers into structured longitudinal charts. Instead of screenshots scattered across a phone camera roll, you get a unified timeline where creatinine, hemoglobin, IGF-1, and lipids are all visible as trends across months or years. At $79/year, the subscription covers unlimited uploads and chart access. Upload your labs and chart these biomarkers over time — and bring the chart to your next appointment.

One important clarity: LabHealthCharts organizes and visualizes your data. It does not interpret what your results mean for your health, and it does not provide medical guidance. Trend identification is a tool for better conversations with your care team, not a replacement for them. You can explore the ACE-031 educational page on the site for more background on the compound and its on-site biomarker links.

Key Takeaways

ACE-031 is a fusion protein that blocks the myostatin pathway via the ActRIIA receptor. It produced real lean mass and bone formation signals in clinical trials before the program was paused over vascular safety concerns. The compound remains of active research interest, and the biology it targets is directly relevant to age-related muscle and bone loss.

The biomarkers most worth following in any myostatin-pathway research context are: creatinine and eGFR (muscle mass artifact), hemoglobin and hematocrit (erythropoiesis signal), phosphorus (bone metabolism), bone alkaline phosphatase and P1NP (osteoblast activity), IGF-1 (broader anabolic context), lipids (body composition proxy), and fasting glucose or HbA1c (metabolic health). None of these numbers means much in isolation from its own history.

Practical questions to bring to your clinician: Is my creatinine trend consistent with my muscle mass changes or does it warrant a cystatin C check? Is my hematocrit staying in a safe range? Would bone markers be worth adding to my panel given my age and training history? Would an IGF-1 draw make sense alongside my current labs?

And when you get those results back, a chart that shows all of them moving together is worth more than a PDF that shows each one next to its reference range. Track the trend, not the snapshot.